Target Information

Target General Infomation
Target ID
T22583
Former ID
TTDC00158
Target Name
Sodium/glucose cotransporter 2
Gene Name
SLC5A4
Synonyms
Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Sodium dependent glucose transporter2; SLC5A4
Target Type
Clinical Trial
Disease Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1]
Type 1/2 diabetes [ICD9: 250, 278; ICD10: E08-E13]
Type 2 diabetes [ICD9: 250; ICD10: E11]
Function
Sodium-dependent glucose transporter.
BioChemical Class
Solute:sodium symporter
Target Validation
T22583
UniProt ID
Q9NY91
Sequence
MASTVSPSTIAETPEPPPLSDHIRNAADISVIVIYFLVVMAVGLWAMLKTNRGTIGGFFL
AGRDMAWWPMGASLFASNIGSNHYVGLAGTGAASGVATVTFEWTSSVMLLILGWIFVPIY
IKSGVMTMPEYLKKRFGGERLQVYLSILSLFICVVLLISADIFAGAIFIKLALGLDLYLA
IFILLAMTAVYTTTGGLASVIYTDTLQTIIMLIGSFILMGFAFNEVGGYESFTEKYVNAT
PSVVEGDNLTISASCYTPRADSFHIFRDAVTGDIPWPGIIFGMPITALWYWCTNQVIVQR
CLCGKDMSHVKAACIMCAYLKLLPMFLMVMPGMISRILYTDMVACVVPSECVKHCGVDVG
CTNYAYPTMVLELMPQGLRGLMLSVMLASLMSSLTSIFNSASTLFTIDLYTKMRKQASEK
ELLIAGRIFVLLLTVVSIVWVPLVQVSQNGQLIHYTESISSYLGPPIAAVFVLAIFCKRV
NEQGAFWGLMVGLAMGLIRMITEFAYGTGSCLAPSNCPKIICGVHYLYFSIVLFFGSMLV
TLGISLLTKPIPDVHLYRLCWVLRNSTEERIDIDAEEKSQEETDDGVEEDYPEKSRGCLK
KAYDLFCGLQKGPKLTKEEEEALSKKLTDTSERPSWRTIVNINAILLLAVVVFIHGYYA
Drugs and Mode of Action
Drug(s) RG7201 Drug Info Phase 3 Type 2 diabetes [532723]
SaxaDapa FDC Drug Info Phase 3 Diabetes [530967], [531182]
Remogli ozin-etabonate Drug Info Phase 2 Type 2 diabetes [550338]
Remogliflozin etabonate Drug Info Phase 2 Type 1/2 diabetes [548088]
Blocker ISIS-5GLT2rx Drug Info [551054]
Remogliflozin etabonate Drug Info [550963]
Modulator Remogli ozin-etabonate Drug Info [532334]
RG7201 Drug Info [532723]
SaxaDapa FDC Drug Info [530967], [531182]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
References
Ref 530967Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
Ref 531182The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12.
Ref 532723Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
Ref 548088Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021813)
Ref 550338Clinical pipeline report, company report or official report of Bhv pharma.
Ref 530967Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
Ref 531182The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12.
Ref 532334Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
Ref 532723Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
Ref 550963Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 551054Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.